Allakos INC 10-Q quarterly reports
Quarterly reports, with unaudited financial statements and management’s discussion of the quarter just ended.
ALLK
Allakos INCAllakos Inc. reports Q1 2025 results, highlighted by a merger agreement with Concentra Biosciences following the discontinuation of AK006 development and a strategic review.
ALLK
Allakos INC10-Q: Allakos Inc. Reports Third Quarter 2024 Financial Results and Provides Clinical Development Update
Allakos Inc. announced its third quarter 2024 financial results, highlighting progress in its AK006 clinical program and a reduction in operating expenses following a company reorganization.
ALLK
Allakos INCAllakos Inc. reported a net loss of $97.8 million for the first six months of 2024, alongside updates on their clinical programs and a recent restructuring.
ALLK
Allakos INCAllakos Inc. announced its first quarter 2024 results, highlighting a significant net loss, a restructuring plan, and a focus on its lead product candidate, AK006.